Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.61 |
| ▸ | LOX | P28300 | 2/20 | 0.61 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.47 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.46 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 4/20 | 0.42 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29223016 | 0.90 | LOXL2 (0.54) | LOXL2LOXPLA2G7FFAR1NR3C2 | |
| SCHEMBL6377136 | 0.86 | LOXL2 (0.61) | LOXL2LOXPLA2G7FFAR1MAOB | |
| SCHEMBL2963636 | 0.83 | LOX (0.54) | LOXL2LOXABCB1 | |
| SCHEMBL12093687 | 0.81 | LOXL2 (0.65) | LOXL2LOXPLA2G7FFAR1NR3C2 | |
| SCHEMBL12093676 | 0.80 | LOXL2 (0.62) | LOXL2LOXPLA2G7FFAR1NR3C2 | |
| SCHEMBL2497237 | 0.80 | LOXL2 (0.62) | LOXL2LOXPLA2G7FFAR1NR3C2 | |
| SCHEMBL6218599 | 0.80 | LOXL2 (0.73) | LOXL2LOXFFAR1MAOB | |
| SCHEMBL22336235 | 0.80 | LOXL2 (0.68) | LOXL2LOXPLA2G7FFAR1NR3C2 | |
| SCHEMBL31583016 | 0.80 | LOXL2 (0.62) | LOXL2LOXPLA2G7FFAR1NR3C2 | |
| SCHEMBL14486857 | 0.80 | LOXL2 (0.62) | LOXL2LOXPLA2G7FFAR1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117702142-A | C (C) 4 Process for preparing substituted pyridine derivatives | 五邑大学 | 2024-03-15 | — | — | CN | disclosed |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2017-07-20 | — | — | US | disclosed |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2017-07-20 | — | — | US | disclosed |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2017-07-20 | — | — | US | disclosed |
| US-9650378-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650378-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-9650378-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | HARMONY BIOSCIENCES, LLC | 2016-06-09 | — | — | US | disclosed |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | HARMONY BIOSCIENCES, LLC | 2016-06-09 | — | — | US | disclosed |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | HARMONY BIOSCIENCES, LLC | 2016-06-09 | — | — | US | disclosed |
| US-20100105679-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20100105679-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| EP-2121654-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | Albany Molecular Research, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009089482-A1 | (1-AZINONE) -SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009089482-A1 | (1-AZINONE) -SUBSTITUTED PYRIDOINDOLES AS MCH ANTAGONISTS | ALBANY MOLECULAR RESEARCH, INC. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2008086404-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008086404-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105679-A1 | 5-PYRIDINONE SUBSTITUTED INDAZOLES | CYP3A5, PDXK, PNPO | LOXL2 2868/4885LOX 1175/4885PLA2G7 2324/4885 |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | LOXL2 2958/4885LOX 2698/4885PLA2G7 3863/4885 |
| US-20090275590-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR0B1, NR3C1 | LOXL2 2959/4885LOX 2568/4885PLA2G7 3916/4885 |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | LOXL2 2958/4885LOX 2698/4885PLA2G7 3863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.